CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Potential anti-tumor activity of kefir-induced juglone and resveratrol fractions against ehrlich ascites carcinoma-bearing balb/c mice
Authors
E. Atay
E. Bozkurt
+6 more
A. Ertekin
Ö.A. Korkmaz
G. Pektaş
M.B. Pektaş
Gökhan Sadi
A. Vurmaz
Publication date
1 January 2020
Publisher
Iranian Journal of Pharmaceutical Research
Doi
Cite
Abstract
We investigated the potential influence of kefir-induced juglone and resveratrol fractions (JRK) against Ehrlich Ascites Carcinoma (EAC) bearing BALB/c male mice. Kefir yeast was grown in the cell culture supplemented with juglone and resveratrol (1:2). After 48 h incubation, JRK solution was applied (0.1 mL/day i.p.) to the EAC-bearing mice throughout five days. Molecular regulatory mechanisms of apoptotic and anti-apoptotic pathway components were evaluated in the plasma of mice and isolated EAC cells with ELISA, qRT-PCR, and immunocytchemical experiments. EAC-induced upregulation in Bcl-2 and downregulation in Caspase-3 were normalized with JRK in the plasma of mice. Additionally, JRK upregulated the expression levels of apoptotic Bax, p53, Caspase-3,8,9, and APAF-1 proteins together with BAX, CASPASE-8, and CASPASE-9 genes in isolated EAC cells. These changes were also associated with decreased expression levels of anti-apoptotic Bcl-2 and Bcl-xl proteins. Immunocytochemical studies also confirmed the activation of apoptotic pathways and repression of anti-apoptotic proteins in EAC cells with JRK treatment. JRK activates apoptotic pathway and inhibits anti-apoptotic genes and proteins in Ehrlich ascites carcinoma-bearing BALB/c mice that could be beneficial in cancer treatment. © 2020, Iranian Journal of Pharmaceutical Research. All rights reserved
Similar works
Full text
Available Versions
DSpace@KMU
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:earsiv.kmu.edu.tr:11492/39...
Last time updated on 13/01/2021